XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.4
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 146 Months Ended
Apr. 30, 2022
Apr. 30, 2016
Nov. 30, 2009
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
License agreements              
Revenues       $ 3,394,635 $ 2,986,267 $ 2,666,702  
United States              
License agreements              
Revenues       3,200,000 2,900,000 2,600,000  
JAKAFI              
License agreements              
Revenues       2,409,225 2,134,508 1,937,850  
Novartis              
License agreements              
Revenues       60,000 0 170,000  
Novartis | Development Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             $ 157,000
Novartis | Development Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 174,000        
Novartis | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             340,000
Novartis | Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     495,000        
Novartis | Commercialization Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone             200,000
Novartis | Commercialization Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 500,000        
Novartis | GVHD | Development and Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement   $ 75,000          
Novartis | JAKAVI              
License agreements              
Revenues       $ 331,600 338,000 277,900  
Novartis | JAKAVI | Minimum              
License agreements              
Royalty payments on future global net sales       12.00%      
Novartis | JAKAVI | Maximum              
License agreements              
Royalty payments on future global net sales       14.00%      
Novartis | JAKAVI | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone $ 45,000            
Novartis | JAKAFI | United States              
License agreements              
Revenues       $ 113,100 99,600 89,900  
Royalties payable       253,500 148,100   $ 148,100
Novartis | TABRECTA              
License agreements              
Revenues       $ 15,400 $ 10,400 $ 4,100  
Novartis | TABRECTA | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone $ 15,000